Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
18.95
-1.86 (-8.94%)
At close: Sep 23, 2026, 4:00 PM EDT
18.75
-0.20 (-1.06%)
Pre-market: Sep 24, 2026, 8:47 AM EDT
Sarepta Therapeutics Revenue
Sarepta Therapeutics had revenue of $401.25M in the quarter ending June 30, 2026, a decrease of -34.34%. This brings the company's revenue in the last twelve months to $1.97B, down -20.44% year-over-year. In the year 2025, Sarepta Therapeutics had annual revenue of $2.20B with 15.58% growth.
Revenue (ttm)
$1.97B
Revenue Growth
-20.44%
P/S Ratio
1.01
Revenue / Employee
$2,364,484
Employees
835
Market Cap
2.00B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.20B | 296.26M | 15.58% |
| Dec 31, 2024 | 1.90B | 658.64M | 52.97% |
| Dec 31, 2023 | 1.24B | 310.32M | 33.26% |
| Dec 31, 2022 | 933.01M | 231.13M | 32.93% |
| Dec 31, 2021 | 701.89M | 161.79M | 29.96% |
| Dec 31, 2020 | 540.10M | 159.27M | 41.82% |
| Dec 31, 2019 | 380.83M | 79.80M | 26.51% |
| Dec 31, 2018 | 301.03M | 146.45M | 94.74% |
| Dec 31, 2017 | 154.58M | 149.16M | 2,751.58% |
| Dec 31, 2016 | 5.42M | 4.17M | 332.64% |
| Dec 31, 2015 | 1.25M | -8.50M | -87.16% |
| Dec 31, 2014 | 9.76M | -4.46M | -31.38% |
| Dec 31, 2013 | 14.22M | -23.11M | -61.91% |
| Dec 31, 2012 | 37.33M | -9.66M | -20.56% |
| Dec 31, 2011 | 46.99M | 17.57M | 59.72% |
| Dec 31, 2010 | 29.42M | 11.84M | 67.30% |
| Dec 31, 2009 | 17.59M | -3.67M | -17.28% |
| Dec 31, 2008 | 21.26M | 10.27M | 93.52% |
| Dec 31, 2007 | 10.99M | 10.87M | 9,428.06% |
| Dec 31, 2006 | 115.29K | -4.67M | -97.59% |
| Dec 31, 2005 | 4.78M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Lakefront Biotherapeutics NV | 1.13B |
| Vericel | 306.30M |
| UroGen Pharma | 188.73M |
| Nuvation Bio | 169.90M |
| Mesoblast | 120.25M |
| Agios Pharmaceuticals | 98.34M |
| Recursion Pharmaceuticals | 54.86M |
| Zenas BioPharma | 1.00M |
SRPT News
- 10 days ago - Sarepta Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 15 days ago - Jefferies says definitive readthrough to Sarepta from Novartis news ‘premature’ - TheFly
- 15 days ago - Mizuho sees Sarepta selloff on Novartis DM1 miss as overdone - TheFly
- 15 days ago - Dyne, Sarepta shares tumble as Novartis setback weighs on muscle disease drug developers - Reuters
- 15 days ago - H.C. Wainwright reiterates Sell on Sarepta after Novartis study miss - TheFly
- 16 days ago - Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for the 2026-2027 Academic Year - Business Wire
- 19 days ago - Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT - PRNewsWire
- 23 days ago - Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference - Business Wire